Cyclosporin A and atherosclerosis--cellular pathways in atherogenesis.

[1]  A. Ragheb,et al.  Attenuated Combined Action of Cyclosporine A and Hyperlipidemia on Atherogenesis in Rabbits by Thymoquinone , 2011, Evidence-based complementary and alternative medicine : eCAM.

[2]  P. Bernardi,et al.  Signal transduction to the permeability transition pore , 2010, FEBS letters.

[3]  Xiaohui Zha,et al.  Cholesterol efflux to apoA-I in ABCA1-expressing cells is regulated by Ca2+-dependent calcineurin signaling , 2010, Journal of Lipid Research.

[4]  T. V. van Berkel,et al.  High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis. , 2010, Current pharmaceutical design.

[5]  D. G. Souza,et al.  Long-term cyclosporine treatment in non-transplanted rats and metabolic risk factors of vascular diseases. , 2010, Chemico-biological interactions.

[6]  S. Garvey,et al.  Cyclosporine Up-Regulates Krüppel-Like Factor-4 (KLF4) in Vascular Smooth Muscle Cells and Drives Phenotypic Modulation In Vivo , 2010, Journal of Pharmacology and Experimental Therapeutics.

[7]  O. Borst,et al.  EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. , 2010, Atherosclerosis.

[8]  Gavin W K Wong,et al.  Effect of cyclosporine on blood pressure. , 2010, The Cochrane database of systematic reviews.

[9]  M. Bukrinsky,et al.  A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. , 2010, Angewandte Chemie.

[10]  Y. M. Lee,et al.  Differential functions of genes regulated by VEGF–NFATc1 signaling pathway in the migration of pulmonary valve endothelial cells , 2010, FEBS letters.

[11]  R. Tan,et al.  Apolipoprotein-mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. , 2009, Blood.

[12]  Liwu Li,et al.  An Innate Immunity Signaling Process Suppresses Macrophage ABCA1 Expression through IRAK-1-Mediated Downregulation of Retinoic Acid Receptor α and NFATc2 , 2009, Molecular and Cellular Biology.

[13]  S. Javadov,et al.  Mitochondrial Permeability Transition Pore Opening as a Promising Therapeutic Target in Cardiac Diseases , 2009, Journal of Pharmacology and Experimental Therapeutics.

[14]  N. Mewton,et al.  Inhibition of mitochondrial permeability transition pore opening: translation to patients. , 2009, Cardiovascular research.

[15]  K. Gaus,et al.  Cyclosporin A Decreases Apolipoprotein E Secretion from Human Macrophages via a Protein Phosphatase 2B-dependent and ATP-binding Cassette Transporter A1 (ABCA1)-independent Pathway* , 2009, The Journal of Biological Chemistry.

[16]  O. Wagner,et al.  The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation , 2009, Thrombosis and Haemostasis.

[17]  M. Kitamura,et al.  Suppression of NF-κB by Cyclosporin A and Tacrolimus (FK506) via Induction of the C/EBP Family: Implication for Unfolded Protein Response1 , 2009, The Journal of Immunology.

[18]  Tetsuya Matoba,et al.  Cyclophilin A enhances vascular oxidative stress and development of angiotensin II-induced aortic aneurysms , 2009, Nature Medicine.

[19]  K. Ley,et al.  Immune and inflammatory mechanisms of atherosclerosis (*). , 2009, Annual review of immunology.

[20]  Ashok Kumar,et al.  HIV-1 Nef Inhibits Lipopolysaccharide-induced IL-12p40 Expression by Inhibiting JNK-activated NFκB in Human Monocytic Cells* , 2009, Journal of Biological Chemistry.

[21]  J. Redondo,et al.  A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants. , 2009, Molecular cell.

[22]  E. Moilanen,et al.  Calcineurin inhibitors down-regulate iNOS expression by destabilizing mRNA. , 2009, International immunopharmacology.

[23]  Y. Ishikawa,et al.  The Rough Endoplasmic Reticulum-resident FK506-binding Protein FKBP65 Is a Molecular Chaperone That Interacts with Collagens* , 2008, Journal of Biological Chemistry.

[24]  G. Marchesini,et al.  Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  P. Witting,et al.  Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. , 2008, Antioxidants & redox signaling.

[26]  Pierre Croisille,et al.  Effect of cyclosporine on reperfusion injury in acute myocardial infarction. , 2008, The New England journal of medicine.

[27]  K. Wasan,et al.  Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma. , 2008, International journal of pharmaceutics.

[28]  Wen-hui Zhou,et al.  Cyclosporin A promotes growth and invasiveness in vitro of human first-trimester trophoblast cells via MAPK3/MAPK1-mediated AP1 and Ca2+/calcineurin/NFAT signaling pathways. , 2008, Biology of reproduction.

[29]  I. Rozenberg,et al.  Cyclophilin A differentially activates monocytes and endothelial cells: role of purity, activity, and endotoxin contamination in commercial preparations. , 2008, Atherosclerosis.

[30]  L. Rohrer,et al.  Apolipoprotein A-I but not high-density lipoproteins are internalised by RAW macrophages: roles of ATP-binding cassette transporter A1 and scavenger receptor BI , 2008, Journal of Molecular Medicine.

[31]  Jiahuai Han,et al.  Calcineurin Negatively Regulates TLR-Mediated Activation Pathways1 , 2007, The Journal of Immunology.

[32]  Haixiang Yu,et al.  Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, in cardiovascular disorders. , 2007, Cardiovascular drug reviews.

[33]  G. Siest,et al.  Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. , 2007, Basic & clinical pharmacology & toxicology.

[34]  M. Moradi,et al.  Hyperlipidemia after renal transplantation and its relation to graft and patient survival. , 2007, Transplantation proceedings.

[35]  M. Walkinshaw,et al.  Cyclosporins. Structure-activity relationships. , 2006, Annals of the New York Academy of Sciences.

[36]  S. Barik.  Immunophilins: for the love of proteins , 2006, Cellular and Molecular Life Sciences CMLS.

[37]  N. Wong,et al.  Cyclosporin A inhibits apolipoprotein AI gene expression. , 2006, Journal of molecular endocrinology.

[38]  A. Ojo.  Cardiovascular Complications After Renal Transplantation and Their Prevention , 2006, Transplantation.

[39]  S. Yokoyama,et al.  Cyclosporin A inhibits apolipoprotein A-I-induced early events in cellular cholesterol homeostasis in rat astrocytes , 2006, Neuropharmacology.

[40]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[41]  M. Walkinshaw,et al.  The chaperone function of cyclophilin 40 maps to a cleft between the prolyl isomerase and tetratricopeptide repeat domains , 2006, FEBS letters.

[42]  A. Tedgui,et al.  Cytokines in atherosclerosis: pathogenic and regulatory pathways. , 2006, Physiological reviews.

[43]  M. Moghadasian.  Dietary Phytosterols Reduce Cyclosporine-Induced Hypercholesterolemia in Apolipoprotein E-Knockout Mice , 2006, Transplantation.

[44]  A. Książek,et al.  A Long-Term Study of Dyslipidemia and Dyslipoproteinemia in Stable Post-Renal Transplant Patients , 2006, Renal failure.

[45]  T. Ichiki.  Role of cAMP Response Element Binding Protein in Cardiovascular Remodeling: Good, Bad, or Both? , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[46]  F. Sacks,et al.  Apolipoprotein-mediated pathways of lipid antigen presentation , 2005, Nature.

[47]  U. Ruegg,et al.  Cyclosporin A generates superoxide in smooth muscle cells , 2005, Free radical research.

[48]  Chunxiang Zhang,et al.  Blockade of Nuclear Factor of Activated T Cells Activation Signaling Suppresses Balloon Injury-induced Neointima Formation in a Rat Carotid Artery Model* , 2005, Journal of Biological Chemistry.

[49]  K. Naseem.  The role of nitric oxide in cardiovascular diseases. , 2005, Molecular aspects of medicine.

[50]  H. Yamawaki,et al.  Cyclosporin A Inhibits Flow-mediated Activation of Endothelial Nitric-oxide Synthase by Altering Cholesterol Content in Caveolae* , 2004, Journal of Biological Chemistry.

[51]  Jonathan D. Smith,et al.  Cyclosporin A Traps ABCA1 at the Plasma Membrane and Inhibits ABCA1-Mediated Lipid Efflux to Apolipoprotein A-I , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[52]  Liang Xie,et al.  Cyclophilin A Is a Proinflammatory Cytokine that Activates Endothelial Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[53]  O. Kocaman,et al.  Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. , 2004, Transplantation proceedings.

[54]  I. Holme,et al.  Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post‐Hoc Subgroup Analyses of the ALERT Study , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[55]  Z. Galis,et al.  Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. , 2004, The American journal of pathology.

[56]  H. Nishimatsu,et al.  Calcineurin Promotes the Expression of Monocyte Chemoattractant Protein-1 in Vascular Myocytes and Mediates Vascular Inflammation , 2004, Circulation research.

[57]  G. Cagney,et al.  Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. , 2004, Blood.

[58]  C. Monaco,et al.  Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. , 2004, Cardiovascular research.

[59]  H. Seo,et al.  Cyclosporin A Enhances Interleukin-8 Expression by Inducing Activator Protein-1 in Human Aortic Smooth Muscle Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[60]  R. Hof,et al.  Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice , 2003, Transplantation.

[61]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[62]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[63]  R. Stocker,et al.  The use of antioxidant supplements in coronary heart disease. , 2002, Atherosclerosis.

[64]  L. Miller.  Cardiovascular Toxicities of Immunosuppressive Agents , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[65]  Christopher P. Johnson,et al.  Cyclosporine A Enhances Leukocyte Binding by Human Intestinal Microvascular Endothelial Cells through Inhibition of p38 MAPK and iNOS , 2002, The Journal of Biological Chemistry.

[66]  T. Michel,et al.  Dephosphorylation of Endothelial Nitric-oxide Synthase by Vascular Endothelial Growth Factor , 2002, The Journal of Biological Chemistry.

[67]  E. Moilanen,et al.  Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines. , 2002, European journal of pharmacology.

[68]  N. Javitt.  25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. , 2002, Journal of lipid research.

[69]  G. Stark,et al.  NFκB-dependent signaling pathways , 2002 .

[70]  S. Yokoyama,et al.  Apolipoprotein A-I Induces Translocation of Cholesterol, Phospholipid, and Caveolin-1 to Cytosol in Rat Astrocytes* , 2002, The Journal of Biological Chemistry.

[71]  S. Gabriel,et al.  Posttransplantation diabetes: a systematic review of the literature. , 2002, Diabetes care.

[72]  A. Uittenbogaard,et al.  Cholesteryl Ester Is Transported from Caveolae to Internal Membranes as Part of a Caveolin-Annexin II Lipid-Protein Complex* , 2002, The Journal of Biological Chemistry.

[73]  W. Bennett,et al.  Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies , 2001, Current opinion in critical care.

[74]  N. Ichimaru,et al.  Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. , 2001, Atherosclerosis.

[75]  H. Segev,et al.  Transcriptional regulation of the human sterol 27-hydroxylase gene (CYP27) and promoter mapping. , 2001, Atherosclerosis.

[76]  N. Mermod,et al.  Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment , 2001, British journal of pharmacology.

[77]  Shigeo Koyasu,et al.  Two distinct action mechanisms of immunophilin–ligand complexes for the blockade of T‐cell activation , 2000, EMBO reports.

[78]  M. Ivery.  Immunophilins: Switched on protein binding domains? , 2000, Medicinal research reviews.

[79]  N. Vaziri,et al.  Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. , 2000, The Journal of pharmacology and experimental therapeutics.

[80]  B. Kasiske,et al.  Cardiovascular disease after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[81]  J. Navarro-Antolín,et al.  Transcriptional Induction of Endothelial Nitric Oxide Gene by Cyclosporine A , 2000, The Journal of Biological Chemistry.

[82]  P. Meier,et al.  Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. , 2000, Gastroenterology.

[83]  Shailendra B. Patel,et al.  Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2. , 1999, American journal of physiology. Endocrinology and metabolism.

[84]  E. Ros,et al.  Fatty acid composition in low-density lipoproteins from renal transplant recipients. , 1999, Transplantation proceedings.

[85]  B. Nordestgaard,et al.  Effect of cyclosporine on arterial balloon injury lesions in cholesterol-clamped rabbits: T lymphocyte-mediated immune responses not involved in balloon injury-induced neointimal proliferation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[86]  U. Ruegg,et al.  Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. , 1999, Kidney international.

[87]  S. Devaraj,et al.  Cyclosporin A does not increase the oxidative susceptibility of low density lipoprotein in vitro. , 1999, Free radical biology & medicine.

[88]  C. Lutton,et al.  Modulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities by steroids and physiological conditions in hamster. , 1999, Life sciences.

[89]  A. Halestrap,et al.  Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. , 1998, The Biochemical journal.

[90]  A. I. Galán,et al.  Inhibition of biliary glutathione secretion by cyclosporine A in the rat: possible mechanisms and role in the cholestasis induced by the drug. , 1998, Journal of hepatology.

[91]  Y. Ying,et al.  Characterization of a Cytosolic Heat-shock Protein-Caveolin Chaperone Complex , 1998, The Journal of Biological Chemistry.

[92]  A. del Palacio,et al.  Lipid abnormalities in stable liver transplant recipients – effects of cyclosporin, tacrolimus, and steroids , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[93]  I. Björkhem,et al.  Elimination of Cholesterol in Macrophages and Endothelial Cells by the Sterol 27-Hydroxylase Mechanism , 1997, The Journal of Biological Chemistry.

[94]  E. Oetjen,et al.  Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[95]  B. Nordestgaard,et al.  Effect of cyclosporine during initiation of transplant arteriosclerosis. An ultrastructural study in the aorta-transplanted rabbit. , 1997, Atherosclerosis.

[96]  M. Rudin,et al.  Allo- and autotransplantation of carotid artery--a new model of chronic graft vessel disease: evaluation by magnetic resonance imaging and histology. , 1997, Transplantation.

[97]  E. Shaffer,et al.  Cholestatic effects of cyclosporine in the rat. , 1997, Transplantation.

[98]  W. Weimar,et al.  Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. , 1997, Kidney international.

[99]  A. Wallmark,et al.  Reversal of cyclosporine‐inhibited low‐density lipoprotein receptor activity in HepG2 cells by 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors , 1997, Hepatology.

[100]  K. Adeli,et al.  Studies on Intracellular Translocation of Apolipoprotein B in a Permeabilized HepG2 System* , 1997, The Journal of Biological Chemistry.

[101]  Timothy M. Willson,et al.  Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway* , 1997, The Journal of Biological Chemistry.

[102]  L Timmermann,et al.  The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.

[103]  C. Florén,et al.  Cyclosporine inhibits catabolism of low‐density lipoproteins in HepG2 cells by about 25% , 1996, Hepatology.

[104]  A. Marks.  Cellular functions of immunophilins. , 1996, Physiological reviews.

[105]  U. Rüegg,et al.  Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity , 1996, British journal of pharmacology.

[106]  W. Weimar,et al.  Increased low density lipoprotein oxidation in stable kidney transplant recipients. , 1996, Kidney international.

[107]  J. Taylor,et al.  Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. , 1995, The Journal of clinical investigation.

[108]  G. Schonfeld,et al.  Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. , 1995, The Journal of clinical investigation.

[109]  P. Tipping,et al.  Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit. , 1995, Atherosclerosis.

[110]  M. Robertson,et al.  Cholesterol precursor concentration in plasma from patients with chronic renal failure or kidney grafts. , 1995, Clinical Nephrology.

[111]  F. Sobrino,et al.  Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. , 1995, Immunology.

[112]  A. Matsumori,et al.  Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. , 1995, Circulation.

[113]  H. Husi,et al.  Comparative binding studies of cyclophilins to cyclosporin A and derivatives by fluorescence measurements. , 1994, Analytical biochemistry.

[114]  D. Sgoutas,et al.  CYCLOSPORINE INCREASES THE OXIDIZABILITY OF LOW‐DENSITY LIPOPROTEINS IN RENAL TRANSPLANT RECIPIENTS , 1994, Transplantation.

[115]  O. Andersson,et al.  Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[116]  K. Rentsch,et al.  Relation of cyclosporine blood levels to adverse effects on lipoproteins. , 1994, Transplantation.

[117]  H. Princen,et al.  Cotranslational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[118]  P. Libby,et al.  Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[119]  E. A. O'neill,et al.  Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF‐kappa B. , 1994, The EMBO journal.

[120]  M. Cambillau,et al.  Elevated high density lipoprotein concentrations in heart transplant recipients are related to impaired plasma cholesteryl ester transfer and hepatic lipase activity. , 1993, Atherosclerosis.

[121]  D. Spady.  Regulatory effects of individual n-6 and n-3 polyunsaturated fatty acids on LDL transport in the rat. , 1993, Journal of lipid research.

[122]  E. Emeson,et al.  Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. , 1993, The American journal of pathology.

[123]  E. Vilella,et al.  Low-density lipoprotein metabolism in rats treated with cyclosporine. , 1993, Metabolism: clinical and experimental.

[124]  A. Esteller,et al.  Inhibition of biliary lipid and protein secretion by cyclosporine A in the rat. , 1992, Biochemical pharmacology.

[125]  A. Cerami,et al.  Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[126]  A. Gotto,et al.  Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. , 1991, Journal of the American College of Cardiology.

[127]  H. Lodish,et al.  Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum. , 1991, The Journal of biological chemistry.

[128]  F. Kuipers,et al.  Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. , 1991, The Biochemical journal.

[129]  A. Superti-Furga,et al.  Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase. , 1991, The Journal of biological chemistry.

[130]  B. Ryffel,et al.  Pharmacology of cyclosporine (sandimmune). I. Introduction. , 1990, Pharmacological reviews.

[131]  R. Ross,et al.  Vascular effects of cyclosporine A in vivo and in vitro. , 1990, The American journal of pathology.

[132]  G. Crabtree,et al.  Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. , 1989, Science.

[133]  M. Crompton,et al.  Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. , 1988, The Biochemical journal.

[134]  J. Steimer,et al.  On the dose dependency of Cyclosporin a absorption and disposition in healthy volunteers , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[135]  G. Hansson,et al.  Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[136]  C. Cluff,et al.  Cyclosporine inhibits macrophage-mediated antigen presentation. , 1986, Journal of immunology.

[137]  J. A. Lindsey,et al.  THE IMPAIRED ABILITY OF HUMAN MONOCYTES TO STIMULATE AUTOLOGOUS AND ALLOGENEIC MIXED LYMPHOCYTE REACTIONS AFTER EXPOSURE TO CYCLOSPORINE: ASSOCIATED ALTERATIONS OF HLA‐DR EXPRESSION AND PHYSICAL CHARACTERISTICS OF MONOCYTES , 1985, Transplantation.

[138]  B. Kahan,et al.  ALTERATIONS IN RAT PULMONARY MACROPHAGE FUNCTION BY THE IMMUNOSUPPRESSIVE AGENTS CYCLOSPORINE, AZATHIOPRINE, AND PREDNISOLONE , 1983, Transplantation.

[139]  S. Parthasarathy,et al.  Oxidized low-density lipoprotein. , 2010, Methods in molecular biology.

[140]  John Andersson,et al.  Adaptive immunity and atherosclerosis. , 2010, Clinical immunology.

[141]  G. Hansson,et al.  Innate immune signals in atherosclerosis. , 2010, Clinical immunology.

[142]  K. Resch,et al.  Everolimus/Cyclosporine Interactions on Bile Flow and Biliary Excretion of Bile Salts and Cholesterol in Rats , 2004, Digestive Diseases and Sciences.

[143]  P. Vyas,et al.  Differential anti-inflammatory effects of immunosuppressive drugs: Cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production , 2000, Inflammation Research.

[144]  S. Sundseth,et al.  Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells. , 1996, Journal of lipid research.

[145]  W. Eberhardt,et al.  Interleukin 1 beta-induced expression of nitric oxide synthase in rat renal mesangial cells is suppressed by cyclosporin A. , 1995, Biochemical and biophysical research communications.

[146]  D. Keppler,et al.  ATP-dependent export pumps and their inhibition by cyclosporins. , 1994, Advances in enzyme regulation.

[147]  F. Sobrino,et al.  Modulation of the inhibition of respiratory burst in mouse macrophages by cyclosporin A: effect of in vivo treatment, glucocorticoids and the state of activation of cells. , 1991, Immunology.

[148]  T. Payne,et al.  Cyclosporine: intrinsic binding energies to interpret structure-activity relationships. , 1989, Progress in clinical and biological research.

[149]  M. Röllinghoff,et al.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2 , 1981, European journal of immunology.

[150]  Research Paper Mediators of Inflammation, 9, 169–174 (2000) , 2022 .